Market Place
Sourcing Support
Revalesio To Showcase Rns60`s Hospital Stay Reduction Potential
19 Nov 2025 //
PR NEWSWIRE
Revalesio To Unveil RNS60 Data From RESCUE Trial At World Stroke
21 Oct 2025 //
PR NEWSWIRE
FDA Fast Tracks Revalesio`s RNS60 for Ischemic Stroke Treatment
31 Jul 2025 //
PR NEWSWIRE
Revalesio Publishes Ph 2 Results for RNS60 in Acute Ischemic
21 Jul 2025 //
PR NEWSWIRE
Revalesio to Present RNS60 Phase 3 Stroke Trial Design
14 Jul 2025 //
PR NEWSWIRE
Revalesio Shares New RNS60 Stroke Trial Data
21 May 2025 //
PR NEWSWIRE
Revalesio`s RNS60 Shortens Hospital Stay for Stroke Patients
09 Apr 2025 //
PR NEWSWIRE
Revalesio Presents New Ph 2 Data on RNS60 in Acute Ischemic Stroke
05 Feb 2025 //
PR NEWSWIRE
Revalesio`s Investigational Treatment Protects Mitochondria In Model
09 Oct 2024 //
PR NEWSWIRE
Revalesio’s RNS60 Extended ALS Survival In Post-Hoc Analysis Of Phase 2 Trial
17 Sep 2024 //
PR NEWSWIRE
Revalesio Announces Positive Topline Data From Phase 2 Rescue Study Of Rns60
07 Feb 2024 //
PR NEWSWIRE
Revalesio Shows Design of RESCUE Phase 2 Trial of RNS60 in Acute Ischemic Stroke
18 Feb 2022 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.